MedPath

Estimation of Pentrexin-3 Levels in GCF and Saliva of Patients With Periodontal Disease

Completed
Conditions
Chronic Periodontitis
Aggressive Periodontitis
Registration Number
NCT03128502
Lead Sponsor
Cairo University
Brief Summary

Subjects were selected from the outpatient clinic, Department of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Cairo University. Ten healthy control subjects presented with clinically healthy periodontium. Ten patients who had plaque induced gingivitis. Ten patients who had generalized chronic periodontitis. Ten patients who had generalised aggressive periodontitis. Pentraxin-3 levels were evaluated in GCF and saliva of all subjects included in this study with ELISA technique.

Detailed Description

The study population consisted of 4 groups of forty patients selected as follows:

Group 1 - Healthy Controls:

Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.

Group 2 - Plaque induced gingivitis patients:

Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.

Group 3 - Chronic periodontitis group:

Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.

Group 4 - Aggressive periodontitis group:

Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL \>5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).

GCF and saliva samples were collected for all patients. Pentraxin-3 levels were evaluated in GCF and saliva of all subjects included in this study with ELISA technique.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • patients with plaque induced gingivitis
  • patients with chronic periodontitis
  • patients with aggressive periodontitis
Read More
Exclusion Criteria
  • Patients with any systemic disease according to Cornell medical index (1968).
  • Patients taking any medications or antibiotics in the last 3 months.
  • Current or former smoker patients.
  • Pregnant females.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
GCF and salivary pentraxin-3 levelsbaseline

levels of pentraxin-3 in GCF and saliva

Secondary Outcome Measures
NameTimeMethod
gingival indexbaseline

Performed using the gingival index of Lӧe (1967)

plaque indexbaseline

Oral hygiene status of the patients were recorded using the plaque index of Silness \& Lӧe (1964)

probing pocket depthbaseline

The depths of the periodontal pockets were measured as the distance from the gingival margin to the base of the pocket using periodontal probe with William's graduation.

clinical attachment levelbaseline

Clinical attachment levels were measured as the distance from the CEJ to the base of the pocket using William's graduated periodontal probe.

© Copyright 2025. All Rights Reserved by MedPath